GS
KYTX icon

Gilead Sciences’s Kyverna Therapeutics KYTX Stock Holding History

Gilead Sciences’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.8M Hold
4,126,119
– – 2.23% 4
2026
Q1 		$35.6M Hold
4,126,119
– – 1.68% 5
2025
Q4 		$38.8M Hold
4,126,119
– – 2% 5
2025
Q3 		$24.8M Hold
4,126,119
– – 1.38% 7
2025
Q2 		$12.7M Hold
4,126,119
– – 0.99% 7
2025
Q1 		$7.96M Hold
4,126,119
– – 0.67% 6
2024
Q4 		$15.4M Buy
+4,126,119
New +$19.8M 0.99% 6

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gilead Sciences's KYTX Position: Q2 2026 in Review

Gilead Sciences held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 4,126,119 shares worth $36.8M. The position accounts for 2.23% of the portfolio, ranked #4.

Gilead Sciences first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $38.8M in Q4 2025. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Gilead Sciences held 4,126,119 shares of Kyverna Therapeutics worth $36.8M as of Q2 2026.
  • Gilead Sciences left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up 2.23% of Gilead Sciences's portfolio in Q2 2026, its #4 holding.
  • Gilead Sciences first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Gilead Sciences's Kyverna Therapeutics position peaked at $38.8M in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.